Benzinga | Sep 24, 2021 04:49AM EDT

Raymond James Upgrades Allogene Therapeutics to Outperform, Announces $36 Price Target

Raymond James analyst Dane Leone upgrades Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Outperform and announces $36 price target.